David Lubner has more than 20 years of finance and executive leadership experience and served as Executive Vice President and Chief Financial Officer (CFO) of Ra Pharma, acquired by UCB Pharma in April 2020. Before joining Ra Pharma, David served as Senior Vice President, CFO at Tetraphase Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel antibiotics for the treatment of serious and life-threatening multidrug-resistant (MDR) bacterial infections. He also held CFO roles at PharMetrics, Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. In addition, David serves on the Board of Directors of Dyne Therapeutics (Nasdaq: DYN), Therapeutics Acquisition Corporation (Nasdaq: RACA), and several other private companies and previously served on the Board of Directors of Nightstar Therapeutics until its acquisition by Biogen in June 2019. He is a Certified Public Accountant (CPA) in the Commonwealth of Massachusetts and a member of the American Institute of CPAs. David received his bachelor’s degree in accounting and business management from Northeastern University and a master’s degree in taxation from Bentley University.